BNTX Jan 2026 125.000 put
| Previous close | 38.50 |
| Open | 38.50 |
| Bid | 32.90 |
| Ask | 36.00 |
| Strike | 125.00 |
| Expiry date | 2026-01-16 |
| Day's range | 38.50 - 38.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
BenzingaEuropean Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte
GlobeNewswireBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders. “The past few years marked a leap in competence for BioNTech,” said He
Simply Wall St.We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Key Insights BioNTech will host its Annual General Meeting on 17th of May CEO Ugur Sahin's total compensation includes...
